Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Foley

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Science (New York, N.Y.)|April 6, 2023
In Science JournalsCourtney S Malo, Priscilla N Kelly, Yury Suleymanov, et al.
Science (New York, N.Y.)|January 18, 2024
In Science JournalsBrent Grocholski, Yury Suleymanov, Bianca Lopez, et al.
Science (New York, N.Y.)|January 26, 2023
In Science JournalsKeith T Smith, Dorothy L Hallberg, Michael A Funk, et al.
The Lancet. Neurology|April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trialJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed careChristopher J Barnes, Christina Caon, John F Foley, et al.
Science (New York, N.Y.)|October 26, 2023
In Science JournalsIan S Osborne, Madeleine Seale, John F Foley, et al.
Science (New York, N.Y.)|March 10, 2022
In Science JournalsBrent Grocholski, Stella M Hurtley, Kip Hodges, et al.
Science (New York, N.Y.)|July 25, 2024
In Science JournalsJesse Smith, Michael A Funk, Peter Stern, et al.
Science (New York, N.Y.)|November 30, 2023
In Science JournalsDi Jiang, Jake S Yeston, Hannah M Isles, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
Science (New York, N.Y.)|April 6, 2023
In Science JournalsCourtney S Malo, Priscilla N Kelly, Yury Suleymanov, et al.
Science (New York, N.Y.)|January 18, 2024
In Science JournalsBrent Grocholski, Yury Suleymanov, Bianca Lopez, et al.
Science (New York, N.Y.)|January 26, 2023
In Science JournalsKeith T Smith, Dorothy L Hallberg, Michael A Funk, et al.
The Lancet. Neurology|April 28, 2022
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trialJohn F Foley, Gilles Defer, Lana Zhovtis Ryerson, et al.
Journal of Managed Care Pharmacy : JMCP|February 7, 2013
Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed careChristopher J Barnes, Christina Caon, John F Foley, et al.
Science (New York, N.Y.)|October 26, 2023
In Science JournalsIan S Osborne, Madeleine Seale, John F Foley, et al.
Science (New York, N.Y.)|March 10, 2022
In Science JournalsBrent Grocholski, Stella M Hurtley, Kip Hodges, et al.
Science (New York, N.Y.)|July 25, 2024
In Science JournalsJesse Smith, Michael A Funk, Peter Stern, et al.
Science (New York, N.Y.)|November 30, 2023
In Science JournalsDi Jiang, Jake S Yeston, Hannah M Isles, et al.
Pageof 13